提高2024年Orladeyo收入指引后，BioCryst上涨8%

2024-08-06 03:55

BioCryst Pharmaceuticals (NASDAQ:BCRX) is up ~8% Monday after increasing its full-year outlook for its hereditary angioedema treatment Orladeyo (berotralstat).
The company now sees $420M-$435M, up from $390M-$400M previously.
BioCryst is also maintaining its operating expenses for 2024 at $365M-$375M.
In Q2, the biotech beat on both lines.
In the quarter, BioCryst narrowed its net loss to $12.7M from $75.3M in the year-ago period ($0.06 per share, basic and diluted vs. $0.40.)
In the pipeline, by the end of the year, the company intends to move BCX17725 for Netherton syndrome into the clinic and in 2025, avoralstat for diabetic macular edema into clinical trials as well.

More on BioCryst Pharmaceuticals